Print | Email | Share | Comments (0)

Cedars-Sinai Seeks Type 2 Participants For 3-Year Implantable Device Study

Mar 27, 2008

This press release is an announcement submitted by , and was not written by Diabetes Health.

Cedars-Sinai Medical Center in Los Angeles is seeking participants with type 2 diabetes for a randomized, controlled clinical study to evaluate an implantable device that delivers electrical impulses to the stomach.

The study is part of a national clinical trial to determine the safety and efficacy of the device for possible treatment for overweight patients with type 2 diabetes.

Participants must be 18 to 70 years of age with type 2 diabetes and have a body mass index (BMI) between 28 and 45. Those enrolled will undergo a laparoscopic procedure for implantation of the device, which requires an overnight stay at the hospital.

The device consists of a pulse generator that is implanted under the skin near the stomach and leads that are implanted in the gastric muscle. The treatment is based on a new technology called Gastric Contractility Modulation (GCM) that is designed to sense naturally occurring electrical activity of the stomach in real time and automatically apply electrical stimulation treatment during meals.

The objective of the study is to evaluate the safety and efficacy of the device based on improvement in blood sugar levels (HbA1c). However, impact on weight loss, blood pressure and other clinical and metabolic benchmarks will also be studied.

The device will be implanted for at least 12 months and up to three years. Study subjects will be randomized into control or treatment groups, evaluated weekly and monthly at the beginning of the study, and then periodically for the remainder of the study.

Participants will receive all testing and study-related medical care at no cost and will be compensated for study-related expenses. After the first 12 months, participants will receive semi-annual evaluations for the remaining two years until the U.S. Food and Drug Administration determines its safety and efficacy. All information gathered during the study will be kept confidential.

The study is sponsored by MetaCure (USA), Inc., the company that developed the device, which is called the TANTALUS system.

For more information, please call Colleen Sam at (310) 423-3779 or visit cedars-sinai.edu

Categories: A1c Test, Blood Sugar, Diabetes, Diabetes, Events, Food, Type 2 Issues

Comments

Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...

Registered User Anonymous

Your Name:	Your Email:	X

Recipient's Name:	Recipient's Email:

Your Chosen Username:	Your Email Address:

Chosen Password:	Confirm Password:

Email to a Friend

Cedars-Sinai Seeks Type 2 Participants For 3-Year Implantable Device Study

You May Also Be Interested In...

Comments

Register...

Have Your Say...

Diabetes Health

Topics

Topics

Topics

Diabetes Health Medical Disclaimer

Comment: